Engineering MMP-2 activated nanoparticles carrying B7-H3 bispecific antibodies for ferroptosis-enhanced glioblastoma immunotherapy
R Fan, C Chen, M Mu, D Chuan, H Liu, H Hou… - ACS …, 2023 - ACS Publications
Administration of bispecific antibodies (biAbs) in tumor therapy is limited by their short half-
life and off-target toxicity. Optimized strategies or targets are needed to overcome these …
life and off-target toxicity. Optimized strategies or targets are needed to overcome these …
Application of organoids in precision immunotherapy of lung cancer
H Tian, J Ren, R Mou, Y Jia - Oncology Letters, 2023 - spandidos-publications.com
In immunotherapy, the immune system is modulated in order to treat cancer. Traditional two
dimensional in vitro models and in vivo animal models are insufficient to simulate the …
dimensional in vitro models and in vivo animal models are insufficient to simulate the …
Preclinical mouse models in adoptive cell therapies of cancer.
U Rajčević, A Smole - Slovenian Veterinary Research …, 2022 - search.ebscohost.com
Engineered T cell-based therapies are an advanced approach for cancer immunotherapy
using genetically modified T cells. To date, CD19 and BCMA targeting Chimeric Antigen …
using genetically modified T cells. To date, CD19 and BCMA targeting Chimeric Antigen …